Comparison between Society of Thoracic Surgeons Score and logistic EuroSCORE for predicting mortality in patients referred for transcatheter aortic valve implantation

Ben‐Dor, Itsik; Gaglia, Michael A.; Barbash, Israel M.; Maluenda, Gabriel; Hauville, Camille; González, Manuel A.; Sardi, Gabriel; Laynez-Carnicero, Ana; Torguson, Rebecca; Okubagzi, Petros; Zhang, Xue; Goldstein, Steven A.; Suddath, William O.; Kent, Kenneth M.; Lindsay, Joseph; Satler, Lowell F.; Pichard, Augusto D.; Waksman, Ron

doi:10.1016/j.carrev.2011.04.005

Cited by 76 publications

(42 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, some studies have indicated that it may not be very reliable when used alone to assess risk for TAVI patients; furthermore, its use has not been validated in Asian patients. (14)(15)(16) Despite the lower mean logistic EuroSCORE, our study showed a higher burden of disease comorbidities compared to the SOURCE XT registry, (13) especially in the incidence rates of coronary artery disease (69.5% vs. 44.2%), peripheral vascular disease (27.1% vs. 21.2%) and chronic kidney disease (74.6% vs. 28.9%). Thus, the results of this study must be interpreted with the context that our selected patients were at high risk.…”

Section: A 3bcontrasting

confidence: 54%

Mid-term study of transcatheter aortic valve implantation in an Asian population with severe aortic stenosis: two-year Valve Academic Research Consortium-2 outcomes

Chew¹,

Hon²,

Yip³

et al. 2017

smedj

View full text Add to dashboard Cite

INTRODUCTION Transcatheter aortic valve implantation (TAVI) is an effective treatment for high-risk or inoperativepatients with severe aortic stenosis. Given the unique characteristics of Asian populations, questions regarding mid-term outcomes in Asians undergoing TAVI have yet to be addressed. We evaluated the two-year clinical outcomes of TAVI in an Asian population using Valve Academic Research Consortium-2 definitions.METHODS This prospective study recruited 59 patients from a major academic medical centre in Singapore. The main outcomes were two-year survival rates, peri-procedural complications, symptom improvement, valvular function and assessment of learning curve. RESULTSMean age was 76.8 years (61.0% male), mean body surface area 1.6 m 2 and mean logistic EuroSCORE 18.7%. Survival was 93.2%, 86.0% and 79.1% at 30 days, one year and two years, respectively. At 30 days post TAVI, the rate of stroke was 1.7%, life-threatening bleeding 5.1%, acute kidney injury 25.0%, major vascular complication 5.1%, and new permanent pacemaker implantation 6.8%. 29.3% of TAVI patients were rehospitalised (47.1% cardiovascular-related) within one year. These composite outcomes were measured: device success (93.2%); early safety (79.7%); clinical efficacy (66.1%); and time-related valve safety (84.7%). Univariate analysis found these predictors of two-year all-cause mortality: logistic EuroSCORE (hazard ratio [HR] 1.07; p < 0.001); baseline estimated glomerular filtration rate (HR 0.97; p = 0.048); and acute kidney injury (HR 5.33; p = 0.022). Multivariate analysis identified non-transfemoral TAVI as a predictor of cardiovascular-related two-year mortality (HR 14.64; p = 0.008).CONCLUSION Despite the unique clinical differences in Asian populations, this registry demonstrated favourable midterm clinical and safety outcomes in Asians undergoing TAVI.

show abstract

Section: A 3bcontrasting

confidence: 54%

Mid-term study of transcatheter aortic valve implantation in an Asian population with severe aortic stenosis: two-year Valve Academic Research Consortium-2 outcomes

Chew¹,

Hon²,

Yip³

et al. 2017

smedj

View full text Add to dashboard Cite

show abstract

“…4,[16][17][18] Attempts to investigate whether surgical risk scores, including Euroscore or STS score, could predict poor long-term outcomes have yielded conflicting results. 9,19,20 In our analysis, mortality was higher in patients with multiple comorbidities, as evidenced by higher STS scores. Interestingly, even in patients with high STS scores (between 8 and 15), there was a very significant benefit of TAVR, although there were fewer survivors.…”

Section: Discussionmentioning

confidence: 53%

Long-Term Outcomes of Inoperable Patients With Aortic Stenosis Randomly Assigned to Transcatheter Aortic Valve Replacement or Standard Therapy

et al. 2014

Self Cite

View full text Add to dashboard Cite

Background-The long-term outcomes of transcatheter aortic valve replacement (TAVR) in inoperable patients with severe aortic stenosis remain unknown. Methods and Results-In the Placement of Aortic Transcatheter Valves (PARTNER) study, 358 patients were randomly assigned to TAVR or standard therapy. We report the 3-year outcomes on these patients, and the pooled outcomes for all randomly assigned inoperable patients (n=449) in PARTNER, as well, including the randomized portion of the continued access study (n=91 Continuing medical education (CME) credit is available for this article. Go to http://cme.ahajournals.org to take the quiz.

show abstract

“…STS score and EuroSCORE II seem to be more accurate predictors of mortality but are still insufficient to adequately identify patients for TAVR. [27][28][29][30][31][32][33] A particular disadvantage of all these scoring systems is that conditions such as porcelain aorta, liver cirrhosis, pulmonary hypertension, severe chronic obstructive pulmonary disease, patent coronary bypass grafts, chest radiation, and frailty are not fully taken into consideration. 3,17,33 While a specific scoring system for TAVR is awaited, an individualized clinical decision by the treating team of cardiologists and cardiac surgeons is recommended.…”

Section: Patient Selection For Tavrmentioning

confidence: 99%

“…3,17,33 While a specific scoring system for TAVR is awaited, an individualized clinical decision by the treating team of cardiologists and cardiac surgeons is recommended. 3,27,29,30,33 A number of independent risk factors associated with poor outcome after TAVR has been identified. In the PARTNER Trial, low body mass index, prior stroke, low mean gradient, creatinine level at baseline, prior vascular surgery or stent, and chronic obstructive pulmonary disease requiring oxygen were shown to be predictors of mortality.…”

Section: Patient Selection For Tavrmentioning

confidence: 99%

Transcatheter aortic valve replacement

Damberg¹,

Benstoem²,

Autschbach³

et al. 2013

RRCC

View full text Add to dashboard Cite

Abstract:The standard treatment for symptomatic severe aortic valve stenosis is surgical aortic valve replacement. Over the last decade, transcatheter aortic valve replacement has emerged as an option for patients judged inoperable. It might also constitute an alternative for high-risk patients, even though which patients might benefit from this approach is still being discussed and remains controversial. Transcatheter heart valve replacement is a rapidly spreading technology. However, a number of problems still need to be addressed, such as paravalvular regurgitation, stroke rate, and postoperative conduction disturbances. Further, the durability of transcatheter heart valves remains unclear. Randomized clinical trials and long-term follow-up will help define the role of transcatheter heart valve replacement in aortic stenosis therapy.

show abstract

Comparison between Society of Thoracic Surgeons Score and logistic EuroSCORE for predicting mortality in patients referred for transcatheter aortic valve implantation

Cited by 76 publications

References 14 publications

Mid-term study of transcatheter aortic valve implantation in an Asian population with severe aortic stenosis: two-year Valve Academic Research Consortium-2 outcomes

Mid-term study of transcatheter aortic valve implantation in an Asian population with severe aortic stenosis: two-year Valve Academic Research Consortium-2 outcomes

Long-Term Outcomes of Inoperable Patients With Aortic Stenosis Randomly Assigned to Transcatheter Aortic Valve Replacement or Standard Therapy

Transcatheter aortic valve replacement

Contact Info

Product

Resources

About